Axcella Therapeutics Inc. is working on its comeback to make something else go away. Just before Christmas, Axcella said it was repositioning itself to focus on long COVID-19 and was just granted regulatory guidance on a primary endpoint and study design from the U.K.’s MHRA to conduct a single registration trial of AXA-1125 for those with long COVID fatigue. Axcella will be meeting with the MHRA in the near term to discuss getting an innovative licensing and access pathway application, which is designed to accelerate the approval process. Axcella also has just submitted its IND to the U.S. FDA for a global phase IIb/III study for treating long COVID.
Shanghai Institute of Materia Medica of the Chinese Academy of Sciences and Wuhan Institute of Virology of the Chinese Academy of Sciences have synthesized amide compounds reported to be useful for the treatment of dengue virus infection, skin inflammation, inflammatory joint disease, inflammatory bowel disease and autoimmune disease.
Vaxxas Pty. Ltd. and the Coalition for Epidemic Preparedness Innovations (CEPI) signed a partnership agreement to develop Vaxxas’ vaccine-patch delivery technology in a project that could end the need for frozen storage of mRNA vaccines.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ammax, Astellas, Beigene, Boehringer Ingelheim, Duality, Eli Lilly, Mirati, Opiant, Revive, Seagen, Sinopharm, Specialised.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Abbisko, Atyr, Avidity, Briacell, Cyrano, Exegenesis, Hutchmed, Junshi, Krystal, Novavax, Orphagen, Paratek, Pharmather, Sanofi, Scisparc, Takeda.
In what is claimed as the largest study of how digital technologies were applied to support population level research during the pandemic, scientists at the U.K. Medical Research Council’s epidemiology unit at Cambridge University have reported high, sustained levels of engagement in a fully remote COVID-19 study that ran at a time when visits to a study center were not possible.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Alithea Genomics, Asahi Kasei, Genetik, Ginkgo Bioworks, Medicines Discovery Catapult, Minxray, Pamgene, Seno Medical Instruments, Smi Drug Discovery, Theralink, Xwell, Zoll.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Amgen, Astrazeneca, Harbour, Novo Nordisk, Revive.
RSS
